DexCom (NASDAQ:DXCM) Shares Acquired Sen. John Boozman

Senator John Boozman (R-Arkansas) recently bought shares of DexCom, Inc. (NASDAQ:DXCM). In a filing disclosed on February 15th, the Senator disclosed that they had bought between $1,001 and $15,000 in DexCom stock on January 26th.

Senator John Boozman also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Omnicom Group (NYSE:OMC) on 1/29/2026.
• Purchased $1,001 – $15,000 in shares of Eaton (NYSE:ETN) on 1/29/2026.
• Purchased $1,001 – $15,000 in shares of Caterpillar (NYSE:CAT) on 1/29/2026.
• Sold $1,001 – $15,000 in shares of iShares S&P 500 Growth ETF (NYSEARCA:IVW) on 1/29/2026.
• Sold $1,001 – $15,000 in shares of Fiserv (NASDAQ:FISV) on 1/29/2026.
• Sold $1,001 – $15,000 in shares of Union Pacific (NYSE:UNP) on 1/29/2026.
• Purchased $1,001 – $15,000 in shares of CVS Health (NYSE:CVS) on 1/29/2026.
• Purchased $1,001 – $15,000 in shares of PayPal (NASDAQ:PYPL) on 1/29/2026.
• Sold $1,001 – $15,000 in shares of Micron Technology (NASDAQ:MU) on 1/26/2026.
• Sold $1,001 – $15,000 in shares of abrdn Physical Palladium Shares ETF (NYSEARCA:PALL) on 1/23/2026.

DexCom Stock Performance

NASDAQ:DXCM opened at $73.08 on Friday. The company has a market cap of $28.13 billion, a P/E ratio of 34.80, a P/E/G ratio of 1.41 and a beta of 1.49. DexCom, Inc. has a twelve month low of $54.11 and a twelve month high of $91.87. The company’s 50-day moving average price is $69.49 and its 200-day moving average price is $69.35. The company has a current ratio of 1.88, a quick ratio of 1.59 and a debt-to-equity ratio of 0.45.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, February 12th. The medical device company reported $0.68 EPS for the quarter, beating analysts’ consensus estimates of $0.65 by $0.03. The company had revenue of $1.26 billion during the quarter, compared to the consensus estimate of $1.25 billion. DexCom had a net margin of 17.94% and a return on equity of 32.12%. DexCom’s quarterly revenue was up 13.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.45 EPS. On average, sell-side analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on DXCM shares. JPMorgan Chase & Co. dropped their target price on DexCom from $90.00 to $75.00 and set a “neutral” rating for the company in a report on Friday, October 31st. Piper Sandler reissued an “overweight” rating on shares of DexCom in a report on Thursday, February 5th. Truist Financial reaffirmed a “buy” rating and set a $80.00 target price (down from $82.00) on shares of DexCom in a research note on Tuesday. Argus dropped their price target on shares of DexCom from $100.00 to $90.00 and set a “buy” rating for the company in a research note on Friday, November 7th. Finally, Royal Bank Of Canada cut their price target on shares of DexCom from $100.00 to $85.00 and set an “outperform” rating for the company in a report on Friday, October 31st. Two analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $85.18.

Institutional Investors Weigh In On DexCom

A number of institutional investors have recently made changes to their positions in DXCM. Brighton Jones LLC boosted its position in shares of DexCom by 257.7% during the 4th quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company’s stock worth $1,290,000 after purchasing an additional 11,946 shares during the period. Integrated Wealth Concepts LLC boosted its position in shares of DexCom by 6.3% during the first quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company’s stock worth $227,000 after buying an additional 196 shares during the period. Empowered Funds LLC boosted its position in shares of DexCom by 5.4% during the first quarter. Empowered Funds LLC now owns 8,446 shares of the medical device company’s stock worth $577,000 after buying an additional 436 shares during the period. Focus Partners Wealth grew its stake in shares of DexCom by 13.2% in the first quarter. Focus Partners Wealth now owns 7,218 shares of the medical device company’s stock valued at $493,000 after buying an additional 841 shares in the last quarter. Finally, Inspire Investing LLC purchased a new stake in shares of DexCom in the 2nd quarter valued at $258,000. 97.75% of the stock is currently owned by institutional investors and hedge funds.

About Senator Boozman

John Boozman (Republican Party) is a member of the U.S. Senate from Arkansas. He assumed office on January 3, 2011. His current term ends on January 3, 2029. Boozman (Republican Party) ran for re-election to the U.S. Senate to represent Arkansas. He won in the general election on November 8, 2022. Boozman won re-election in 2016. He faced Democrat Conner Eldridge, Libertarian Frank Gilbert, and write-in candidate Jason Tate in the general election. Arkansas’ U.S. Senate race was rated as safely Republican in 2016. Boozman began his political career in the U.S. House. He won a special election in 2001 and served in that position until his election to the Senate in 2010. Prior to his political career, Boozman worked as an optometrist. As of a 2014 analysis of multiple outside rankings, Boozman is an average Republican member of Congress, meaning he will vote with the Republican Party on the majority of bills. Below is an abbreviated outline of Boozman’s academic, professional, and political career: 2011-Present: U.S. Senator from Arkansas 2001-2011: U.S. Representative from Arkansas 1977: Graduated from Southern College of Optometry

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.